228 related articles for article (PubMed ID: 23122537)
21. MMP13 is potentially a new tumor marker for breast cancer diagnosis.
Chang HJ; Yang MJ; Yang YH; Hou MF; Hsueh EJ; Lin SR
Oncol Rep; 2009 Nov; 22(5):1119-27. PubMed ID: 19787229
[TBL] [Abstract][Full Text] [Related]
22. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
[TBL] [Abstract][Full Text] [Related]
23. MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells.
Lacunza E; Baudis M; Colussi AG; Segal-Eiras A; Croce MV; Abba MC
Cancer Genet Cytogenet; 2010 Sep; 201(2):102-10. PubMed ID: 20682394
[TBL] [Abstract][Full Text] [Related]
24. Testin is a tumor suppressor and prognostic marker in breast cancer.
Zhu J; Li X; Kong X; Moran MS; Su P; Haffty BG; Yang Q
Cancer Sci; 2012 Dec; 103(12):2092-101. PubMed ID: 22957844
[TBL] [Abstract][Full Text] [Related]
25. Expression and clinicopathological significance of oestrogen-responsive ezrin-radixin-moesin-binding phosphoprotein 50 in breast cancer.
Song J; Bai J; Yang W; Gabrielson EW; Chan DW; Zhang Z
Histopathology; 2007 Jul; 51(1):40-53. PubMed ID: 17593079
[TBL] [Abstract][Full Text] [Related]
26. High expression and prognostic role of CAP1 and CtBP2 in breast carcinoma: associated with E-cadherin and cell proliferation.
Liu X; Yao N; Qian J; Huang H
Med Oncol; 2014 Mar; 31(3):878. PubMed ID: 24522810
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow-up study of a prospective multicenter sentinel node trial: molecular detection of breast cancer sentinel node metastases.
Verbanac KM; Min CJ; Mannie AE; Lu J; O'Brien KF; Rosman M; Tafra L;
Ann Surg Oncol; 2010 Oct; 17 Suppl 3():368-77. PubMed ID: 20853060
[TBL] [Abstract][Full Text] [Related]
28. Decreased expression of SOX17 is associated with tumor progression and poor prognosis in breast cancer.
Fu DY; Tan HS; Wei JL; Zhu CR; Jiang JX; Zhu YX; Cai FL; Chong MH; Ren CL
Tumour Biol; 2015 Sep; 36(10):8025-34. PubMed ID: 25971583
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of Breast Ducts in Normal-Risk and High-risk Women and Their Relationship to Ductal Cytologic Atypia.
Danforth DN; Filie AC; Warner AC; Wright GW; Sun Z; Ried T; McGowan CT; Prindiville SA
Cancer Prev Res (Phila); 2020 Dec; 13(12):1027-1036. PubMed ID: 32753377
[TBL] [Abstract][Full Text] [Related]
30. Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression.
Kechagioglou P; Papi RM; Provatopoulou X; Kalogera E; Papadimitriou E; Grigoropoulos P; Nonni A; Zografos G; Kyriakidis DA; Gounaris A
Anticancer Res; 2014 Mar; 34(3):1387-400. PubMed ID: 24596386
[TBL] [Abstract][Full Text] [Related]
31. Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53.
Guo LL; Gao P; Wu YG; Jian WC; Hao CY; Li H; Lin XY
Arch Med Res; 2007 Nov; 38(8):846-52. PubMed ID: 17923265
[TBL] [Abstract][Full Text] [Related]
32. An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas.
Burchell J; Poulsom R; Hanby A; Whitehouse C; Cooper L; Clausen H; Miles D; Taylor-Papadimitriou J
Glycobiology; 1999 Dec; 9(12):1307-11. PubMed ID: 10561455
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical study of Muc1, Muc2 and human gastric mucin in breast carcinoma: relationship with prognostic factors.
Xu Y; Kimura N; Yoshida R; Lin H; Yoshinaga K
Oncol Rep; 2001; 8(5):1177-82. PubMed ID: 11496338
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of TNFAIP8 is associated with tumor aggressiveness and poor prognosis in patients with invasive ductal breast carcinoma.
Xiao M; Xu Q; Lou C; Qin Y; Ning X; Liu T; Zhao X; Jia S; Huang Y
Hum Pathol; 2017 Apr; 62():40-49. PubMed ID: 28087477
[TBL] [Abstract][Full Text] [Related]
35. Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation.
Oka K; Suzuki T; Onodera Y; Miki Y; Takagi K; Nagasaki S; Akahira J; Ishida T; Watanabe M; Hirakawa H; Ohuchi N; Sasano H
Int J Cancer; 2011 Apr; 128(8):1770-82. PubMed ID: 20533549
[TBL] [Abstract][Full Text] [Related]
36. Expression of tight junction molecules in breast carcinomas analysed by array PCR and immunohistochemistry.
Tőkés AM; Szász AM; Juhász E; Schaff Z; Harsányi L; Molnár IA; Baranyai Z; Besznyák I; Zaránd A; Salamon F; Kulka J
Pathol Oncol Res; 2012 Jul; 18(3):593-606. PubMed ID: 22193974
[TBL] [Abstract][Full Text] [Related]
37. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of cyclin D1, β-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast.
Cheng CW; Liu YF; Yu JC; Wang HW; Ding SL; Hsiung CN; Hsu HM; Shieh JC; Wu PE; Shen CY
Ann Surg Oncol; 2012 Dec; 19(13):4129-39. PubMed ID: 22864797
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.
He Q; Peng B; Zhuang D; Xiao L; Zheng L; Fan Z; Zhu J; Xu B; Xu C; Zhao J; Wu L; Zhou P; Hou L; Yu F; Zhao G
Cancer Biomark; 2015; 15(6):823-31. PubMed ID: 26406408
[TBL] [Abstract][Full Text] [Related]
40. Real time PCR analyses of expression of E-cadherin, alpha-, beta- and gamma-catenin in human breast cancer for predicting clinical outcome.
Goyal A; Martin TA; Mansel RE; Jiang WG
World J Surg Oncol; 2008 Jun; 6():56. PubMed ID: 18547424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
